Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19
NCT04389450 is registered in ClinicalTrials.gov with Pluristem Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19
- Lead sponsor
- Pluristem Ltd.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- October 1, 2020
- Completion date
- June 7, 2023
- Enrollment
- 66 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.
ards, covid